David Risinger

David Risinger Analyst Performance

Senior Managing Director & Senior Research Analyst at Leerink Partners

David Risinger is a stock analyst at Leerink Partners focused in the healthcare sector, covering 36 publicly traded companies. Over the past year, David Risinger has issued 41 stock ratings, including buy and hold recommendations. While full access to David Risinger's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Risinger's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
176 Last 11 Years
Buy Recommendations
48.82% 83 Buy Ratings
Companies Covered
36 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy2.4%4 ratings
Buy46.5%79 ratings
Hold47.1%80 ratings
Sell4.1%7 ratings

Out of 170 total stock ratings issued by David Risinger at Leerink Partners, the majority (47.1%) have been Hold recommendations, followed by 46.5% Buy, 4.1% Sell, and 2.4% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
66.7% of companies on NASDAQ
24 companies
NYSE
33.3% of companies on NYSE
12 companies

David Risinger, an analyst at Leerink Partners, currently covers 36 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
34 companies
94.4%
Miscellaneous
2 companies
5.6%

David Risinger of Leerink Partners specializes in stock coverage within the Healthcare sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
18 companies
50.0%
PHARMACEUTICALS
15 companies
41.7%
Miscellaneous
2 companies
5.6%
HEALTHCARE PROVIDERS & SERVICES
1 company
2.8%

About David Risinger

David Risinger, CFA is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Diversified Biopharmaceuticals. Prior to joining the Firm in 2022, David’s most recent Wall Street role was Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to Morgan Stanley, he was head of Global Healthcare Research and Senior US Pharmaceutical analyst at Merrill Lynch & Co. He started his Wall Street career at Dillon, Read & Co. He has been a top-ranked analyst by Institutional Investor for decades, including achieving Runner-Up rankings in both Major Pharmaceuticals and Specialty Pharmaceuticals in 2021. He earned his Bachelor of Arts in Political Science from Bucknell University and holds the Chartered Financial Analyst designation.
Follow on LinkedIn

David Risinger's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
11/6/2026Downgrade$103.63$117.00Hold
Amgen Inc. stock logo
AMGN
Amgen
11/5/2026Boost Price Target$460.28$464.00Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
11/2/2026Boost Price Target$289.67$342.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
11/2/2026Boost Price Target$964.13$997.00Market Perform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
10/21/2026Boost Price Target$1,265.96$1,316.00Outperform
TRAX
First Tracks Biotherapeutics
10/16/2026Boost Price Target$36.04$90.00Outperform
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
10/14/2026Lower Price Target$251.39$272.00Outperform
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
10/5/2026Downgrade$61.16$59.00Market Perform
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
9/23/2026Lower Price Target$53.92$81.00Outperform
Entera Bio Ltd. stock logo
ENTX
Entera Bio
9/18/2026Initiated Coverage$3.03$9.00Outperform
Latigo Biotherapeutics, Inc. stock logo
LTGO
Latigo Biotherapeutics
9/1/2026Initiated Coverage$22.02$36.00Outperform
Latigo Biotherapeutics, Inc. stock logo
LTGO
Latigo Biotherapeutics
9/1/2026Initiated Coverage$22.26$36.00Outperform
Scribe Therapeutics Inc. stock logo
SCTX
Scribe Therapeutics
8/18/2026Initiated Coverage$21.19$37.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
8/17/2026Boost Price Target$803.48$824.00Market Perform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8/14/2026Initiated Coverage$288.22$330.00Outperform
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
8/7/2026Upgrade$85.76$110.00Outperform
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
7/31/2026Boost Price Target$59.18$73.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
6/25/2026Boost Price Target$1,115.98$1,232.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
5/26/2026Set Price Target$1,066.59$1,119.00
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
5/21/2026Set Price Target$32.41$42.00
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
5/15/2026Set Price Target$62.77$90.00
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
5/13/2026Upgrade$224.44$265.00Outperform
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
5/12/2026Initiated Coverage$22.93$36.00Outperform
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
4/30/2026Set Price Target$68.10$120.00
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/30/2026Lower Price Target$746.54$792.00
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
4/28/2026Boost Price Target$66.59$85.00Outperform
TRAX
First Tracks Biotherapeutics
4/24/2026Initiated Coverage$19.00$46.00Outperform
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
4/1/2026Downgrade$39.86$40.00Hold
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
3/16/2026Boost Price Target$41.52$86.00Outperform
Amgen Inc. stock logo
AMGN
Amgen
3/5/2026Reiterated Rating$367.60$355.00Market Perform
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
2/24/2026Reiterated Rating$26.79Outperform
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
2/24/2026Boost Price Target$25.32$50.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2/5/2026Boost Price Target$1,057.10$1,296.00Outperform
Amgen Inc. stock logo
AMGN
Amgen
2/4/2026Boost Price Target$338.59$355.00Outperform
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1/13/2026Boost Price Target$56.40$60.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1/5/2026Set Price Target$1,079.83$1,234.00
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
12/29/2025Boost Price Target$462.90$525.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/18/2025Reiterated Rating$1,062.10Outperform
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
12/15/2025Boost Price Target$22.10$32.00Outperform
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
12/11/2025Lower Price Target$26.76$45.00Outperform
Your free book is about to disappear (Ad)

Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel

Download the Safe Trade Options Formula book for free before access closes
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
11/19/2025Set Price Target$49.53$77.00Outperform
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
11/11/2025Reiterated Rating$21.17$29.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
11/10/2025Upgrade$923.35$1,104.00Outperform
ImageneBio, Inc. stock logo
IMA
ImageneBio
10/24/2025Initiated Coverage$7.39$30.00Outperform
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
10/14/2025Upgrade$67.72$70.00Market Perform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
9/25/2025Upgrade$376.62$456.00Outperform
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
9/18/2025Boost Price Target$15.28$22.00Outperform
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
5/13/2025Downgrade$153.88$153.00Market Perform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
5/6/2025Reiterated Rating$500.19$503.00Market Perform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
5/6/2025Downgrade$450.03$503.00Hold
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2/5/2025Upgrade$697.05$834.00Outperform
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
1/23/2025Lower Price Target$146.81$169.00Outperform